Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Venezuela paid $64 million to receive vaccines through COVAX - vice president

Published 04/10/2021, 03:22 PM
Updated 04/10/2021, 03:25 PM
© Reuters. Outbreak of the coronavirus disease (COVID-19) in Caracas

(Reuters) - Venezuela has paid $64 million, half of the required amount, for doses it is set to receive through the global COVAX program, Vice President Delcy Rodriguez announced Saturday on state television.

"You know that the COVAX mechanism requires an advance - Venezuela has even doubled the required advance," said Rodriguez, adding that the government had deposited "59.2 million Swiss francs in the accounts of GAVI," a co-leader of the COVAX program that seeks to improve low-income countries' access to vaccines.

Rodriguez did not specify what funds the government used to pay for the vaccines.

In recent months the government has held talks with opposition leaders to obtain vaccines via the COVAX program using funds frozen in the United States.

Those efforts had been complicated by President Nicolas Maduro's refusal to accept the AstraZeneca (NASDAQ:AZN) vaccine following reports of blood clotting elsewhere. COVAX this year said it had set aside doses of the AstraZeneca shot for use in Venezuela.

In her announcement, Rodriguez said Venezuelan health authorities were evaluating which vaccines the country would accept, especially considering various variants of the coronavirus, particularly the variant that originated in Brazil.

The vice president highlighted that in September 2020 the government entered into the agreement for over 11 million doses, which would vaccinate around 20% of the population.

Rodriguez added that the remaining $60 million worth were "guaranteed."

COVAX expects to deliver at least 2 billion doses this year and to diversify the offering beyond the AstraZeneca/Oxford and Pfizer/BioNTech shots it is currently supplying.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Venezuela's vaccination campaign is behind most other countries in the region.

It has received about 500,000 doses of the Sinopharm vaccine from China and about 250,000 of Russia’s Sputnik V, of which authorities recently said they expect the arrival of another 30,000 shortly.

Maduro has extended coronavirus lockdown measures several times as the country continues to register high rates of infections.

As of Friday, Venezuelan authorities had registered 172,461 coronavirus cases and 1,739 deaths. Medical unions say the number of cases and deaths are likely much higher.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.